Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease
1 Center for Neuropsychiatric Research, National Health Research Institutes, Zhunan, Taiwan.
2 Graduate Institute of Applied Science and Engineering, Fu-Jen Catholic University, New Taipei, Taiwan.
3 Drug Design and Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.
4 Peptron Inc., Yuseong-gu, Daejeon, Republic of Korea.
5 Department of Neurosurgery, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
6 Drug Design and Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA. [email protected].
7 Center for Neuropsychiatric Research, National Health Research Institutes, Zhunan, Taiwan. [email protected].